While IL-36 cytokines directly contribute to the pathogenesis of psoriasis vulgaris and pustular psoriasis in the skin and the significance of therapeutically targeting IL-36 cytokines has been shown by Bachelez and colleagues who demonstrated the effectiveness of utilising a specific monoclonal antibody against the IL-36R in GPP patients harbouring or lacking IL36RN mutations [64]. This evidence concerns the gene IL1RL2 and pustular psoriasis.